SCHEMBL12571642

SCHEMBL12571642

Cc1c([C@@H](C)NC(=O)c2ccc3nc(C(C)(C)C(F)(F)F)ccc3c2)cnn1C

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ BRPF1 P55201 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ KMT2A Q03164 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ DDR2 Q16832 3/20 0.35
▸ LMNA P02545 1/20 0.33
▸ GFER P55789 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ AKT1 P31749 1/20 0.33
▸ KCNT1 Q5JUK3 4/20 0.33
▸ MAOB P27338 1/20 0.32
▸ HPGDS O60760 1/20 0.32
▸ SLC8A1 P32418 1/20 0.32
▸ PPARG P37231 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1838653 0.93 BRPF1 (0.51) BRPF1KDM4EALDH1A1MAPTKMT2A
SCHEMBL1841353 0.93 BRPF1 (0.51) BRPF1KDM4EALDH1A1MAPTKMT2A
SCHEMBL1844278 0.91 BRPF1 (0.54) BRPF1KDM4EALDH1A1MAPTKMT2A
SCHEMBL1842642 0.91 BRPF1 (0.54) BRPF1KDM4EALDH1A1MAPTKMT2A
SCHEMBL1840878 0.90 BRPF1 (0.41) BRPF1DDR2CDK2AKT1KCNT1
SCHEMBL1839081 0.90 BRPF1 (0.41) BRPF1DDR2CDK2AKT1KCNT1
SCHEMBL1841102 0.90 BRPF1 (0.41) BRPF1DDR2CDK2AKT1KCNT1
SCHEMBL1843752 0.90 BRPF1 (0.41) BRPF1DDR2CDK2AKT1KCNT1
SCHEMBL1841106 0.90 BRPF1 (0.41) BRPF1DDR2CDK2AKT1KCNT1
SCHEMBL1841089 0.90 BRPF1 (0.41) BRPF1DDR2CDK2AKT1KCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964732-B2 Substituted bicyclocarboxyamide compounds PFIZER INC. (US) 2011-06-21 — — US disclosed
US-7964732-B2 Substituted bicyclocarboxyamide compounds PFIZER INC. (US) 2011-06-21 — — US disclosed
US-20100267769-A1 Substituted Bicyclocarboxyamide Compounds Pfizer, Inc. and Renovis Inc. 2010-10-21 — — US disclosed
US-20100267769-A1 Substituted Bicyclocarboxyamide Compounds Pfizer, Inc. and Renovis Inc. 2010-10-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267769-A1 Substituted Bicyclocarboxyamide Compounds TRPV1, OPRL1, CNR1 BRPF1 1691/4885KDM4E 4164/4885ALDH1A1 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback